Pyrimidinones as PI3K inhibitors
AssigneesIncyte Corporation, Incyte Holdings Corporation
InventorsYun-Long Li, Brian W. Metcalf, Andrew P. Combs
Life of this patent
Estimating the term…
Abstract
The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
Claims25
A method of inhibiting an activity of PI3Kδ comprising contacting said PI3Kδ with a compound, which is 7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one, or a pharmaceutically acceptable salt thereof.
A method of treating a disease selected from B cell lymphoma, rheumatoid arthritis, myasthenia gravis, Sjoegren's syndrome, multiple sclerosis, glomerulonephritis, lupus, and inflammation related to rheumatoid arthritis, glomerulonephritis, or lupus, in a patient, comprising administering to said patient a therapeutically effective amount of a compound, which is 7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.